
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Overruled: No More Dual Pricing
Author(s)Kevin Gopal
European Union-The European Commission’s ban on GlaxoSmith–Kline’s dual pricing policy in Spain halts one of Big Pharma’s attempts to prevent parallel imports in Europe.
Advertisement
Articles in this issue
over 24 years ago
Pharmacies: OTC Price Warsover 24 years ago
One Disease at a Timeover 24 years ago
Overview of the Industry: A World of Opportunitiesover 24 years ago
The Power Shiftover 24 years ago
A Giant Stumblesover 24 years ago
Submergedover 24 years ago
Generic ThreatNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
2
ACIP Member Claims FDA Commissioner is Halting Decision to Remove Covid Vaccines from the Market: Report
3
FDA Announces New Domestic-Manufacturing-Focused Pilot Program
4




